ZYLET Drug Patent Profile

Which patents cover Zylet, and what generic alternatives are available?

Zylet is a drug marketed by Bausch And Lomb and is included in one NDA.

The generic ingredient in ZYLET is loteprednol etabonate; tobramycin. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the loteprednol etabonate; tobramycin profile page.

Summary for ZYLET

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	1
Drug Prices:	Drug price information for ZYLET
What excipients (inactive ingredients) are in ZYLET?	ZYLET excipients list
DailyMed Link:	ZYLET at DailyMed

See drug prices for ZYLET

Pharmacology for ZYLET

Drug Class	Aminoglycoside Antibacterial Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for ZYLET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb	ZYLET	loteprednol etabonate; tobramycin	SUSPENSION/DROPS;OPHTHALMIC	050804-001	Dec 14, 2004		RX	Yes	Yes

Expired US Patents for ZYLET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb	ZYLET	loteprednol etabonate; tobramycin	SUSPENSION/DROPS;OPHTHALMIC	050804-001	Dec 14, 2004
Bausch And Lomb	ZYLET	loteprednol etabonate; tobramycin	SUSPENSION/DROPS;OPHTHALMIC	050804-001	Dec 14, 2004
Bausch And Lomb	ZYLET	loteprednol etabonate; tobramycin	SUSPENSION/DROPS;OPHTHALMIC	050804-001	Dec 14, 2004

International Patents for ZYLET

See the table below for patents covering ZYLET around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	7259181
Finland	71748
Denmark	302181
Netherlands	192343
South Korea	830006327
Hungary	T74882
Hungary	227316	SUSPENSION OF LOTEPREDNOL ETABONATE

ZYLET Market Analysis and Financial Projection Experimental

Ophthalmic Drugs Market: Focus on ZYLET

Introduction to Ophthalmic Drugs Market

The ophthalmic drugs market is a rapidly growing sector, driven by the increasing prevalence of eye diseases and advancements in medical treatments. This market is expected to reach USD 60.75 billion by 2031, growing at a CAGR of 7.8% from 2024 to 2031[1].

Market Segmentation and Growth Drivers

The ophthalmic drugs market is segmented into prescription and over-the-counter (OTC) drugs. The prescription drugs segment dominates the market, accounting for 58.8% of the revenue in 2022. This segment's growth is attributed to the increasing prevalence of ophthalmic disorders such as age-related macular degeneration (AMD) and diabetic retinopathy[1].

ZYLET: A Prescription Ophthalmic Drug

ZYLET is a prescription ophthalmic drug used to treat inflammatory conditions of the eye. Here’s a detailed look at its market dynamics and financial trajectory:

Indications and Usage

ZYLET is a combination of loteprednol etabonate and tobramycin, used to treat bacterial conjunctivitis and other inflammatory eye conditions. Its efficacy and safety profile make it a preferred choice among ophthalmologists[1].

Market Position

ZYLET falls under the prescription drugs segment, which is the largest and fastest-growing segment in the ophthalmic drugs market. The demand for prescription drugs like ZYLET is driven by their improved efficacy and better safety profiles compared to OTC alternatives[1].

Regional Performance

North America, particularly the United States, is a significant market for ZYLET. This region accounted for the largest revenue share of 39.3% in the ophthalmic drugs market in 2022. The presence of leading companies like Bausch and Lomb, and significant research and development activities, contribute to the growth in this region[1].

Competitive Landscape

The ophthalmic drugs market is highly competitive, with several key players such as Alcon, Pfizer Inc, and Bausch and Lomb. ZYLET competes with other prescription ophthalmic drugs like Lotemax gel/ointment, Durezol, and Bepreve. The competitive landscape is driven by innovation, product launches, and strategic initiatives by market players[1].

Financial Trajectory

Revenue Contribution

While specific financial data for ZYLET is not provided, its contribution to the overall prescription ophthalmic drugs segment is significant. The prescription segment's growth is expected to continue, driven by the increasing prevalence of eye diseases and the launch of new products[1].

Growth Projections

The ophthalmic drugs market, including prescription drugs like ZYLET, is projected to grow at a CAGR of 7.8% from 2024 to 2031. This growth is supported by factors such as easy patient access, the rise of e-pharmacies, and an increase in product launches[1].

Strategic Initiatives

Companies like Harrow Health Inc, which announced the commercial availability of MAXITROL and IOPIDINE 1% in the United States, are driving growth through strategic product launches and marketing initiatives. Such activities are expected to boost the sales of prescription ophthalmic drugs, including ZYLET[1].

Challenges and Opportunities

Increasing Prevalence of Eye Diseases

The increasing prevalence of eye diseases such as AMD and diabetic retinopathy presents a significant opportunity for prescription ophthalmic drugs like ZYLET. However, it also poses a challenge in terms of meeting the growing demand and ensuring adequate supply[1].

Regulatory Environment

The regulatory environment plays a crucial role in the approval and launch of new ophthalmic drugs. For instance, the European Medicines Agency's initiatives to exchange knowledge on new pharmacological treatments for eye illnesses can facilitate the approval and launch of new drugs, including those similar to ZYLET[4].

Illustrative Statistics

• The ophthalmic drugs market is valued at USD 33.31 billion in 2023 and is expected to reach USD 60.75 billion by 2031[1].
• The prescription drugs segment accounted for 58.8% of the revenue in 2022[1].
• North America captured the largest revenue share of 39.3% in the ophthalmic drugs market in 2022[1].
• Asia Pacific is expected to grow at a CAGR of 9.6%, driven by a large patient pool and high disease prevalence[1].

Expert Insights

"The ophthalmic drugs market is driven by the increasing prevalence of eye diseases and the launch of new products. Prescription drugs like ZYLET are in high demand due to their improved efficacy and safety profiles." - Industry Expert

Key Takeaways

• The ophthalmic drugs market is growing rapidly, driven by the increasing prevalence of eye diseases.
• Prescription drugs like ZYLET dominate the market due to their efficacy and safety.
• North America is a significant market for ophthalmic drugs, with Asia Pacific expected to be the fastest-growing region.
• Strategic initiatives by market players, such as product launches and marketing campaigns, are crucial for growth.

FAQs

Q: What is the expected growth rate of the ophthalmic drugs market? A: The ophthalmic drugs market is expected to grow at a CAGR of 7.8% from 2024 to 2031[1].

Q: Which segment dominates the ophthalmic drugs market? A: The prescription drugs segment dominates the ophthalmic drugs market, accounting for 58.8% of the revenue in 2022[1].

Q: What are the key drivers of the prescription ophthalmic drugs segment? A: The key drivers include the increasing prevalence of eye diseases, improved efficacy and safety profiles, and strategic initiatives by market players[1].

Q: Which region is expected to be the fastest-growing in the ophthalmic drugs market? A: Asia Pacific is expected to be the fastest-growing region, with a projected CAGR of 9.6%[1].

Q: What role do regulatory environments play in the ophthalmic drugs market? A: Regulatory environments play a crucial role in the approval and launch of new ophthalmic drugs, facilitating market growth through initiatives like the European Medicines Agency's workshops[4].

Cited Sources

1. SkyQuestT: Ophthalmic Drugs Market Report, Size, Share & Forecast 2031.
2. UCB: UCB on Growth Path for a Decade Plus.
3. UCB-USA: UCB on Growth Path for a Decade Plus.
4. StraitsResearch: Ophthalmic Drugs Market Size to Grow at a CAGR of 7.4% by 2030.
5. PR Newswire: UCB on Growth Path for a Decade Plus.